secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001140361-25-006961
Event type: litigation
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Opus Genetics receives Sandoz Paragraph IV notice challenging six RYZUMVI patents
--------------------------------------------------------------------------------

- Sandoz filed ANDA for generic RYZUMVI; alleges six Orange Book patents invalid/unenforceable/non-infringed.
- Challenged patents: 9,795,560, 10,278,918, 10,772,829, 11,090,261, 11,844,858, and 11,400,077.
- Two other RYZUMVI Orange Book patents (12,201,615 and 12,201,616) not challenged by Sandoz.
- Opus or its commercial partner may file patent infringement lawsuit to defend IP rights.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125006961/0001140361-25-006961-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125006961/ef20044862_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-006961

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer